ClinicalTrials.gg
CompletedNCT03597464AURORA 2Updated Dec 14, 2022Results posted

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

A Phase 3 interventional study of Voclosporin and Placebo Oral Capsule in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
17th of 100
216 · median 50
Started
2019
with 2 others
Phase 3
16 of 114
2 open now
Registered
43rd of 114
by date
Lead sponsor
7 of 114
Aurinia Pharmaceuticals Inc.

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 17th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 in phase 3, and was the 43rd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).

Read the detailed description

The aim of the Phase 3 continuation study (AURORA 2) is to assess the long-term safety and tolerability of voclosporin, added to the standard of care treatment in LN, for an additional 24 months, following a treatment period of 52 weeks in the AURORA 1 study (AUR-VCS-2016-01). All subjects will continue to receive background therapy of mycophenolate mofetil (MMF) and/or oral corticosteroids starting at the same dose as at the end of the AURORA 1 study. Subjects with LN, who have completed 52 weeks of treatment with study drug in the AURORA 1 study, will be eligible to enter the study. The long-term safety and tolerability of the drug combination will be assessed from its safety profile while demonstrating the continued ability to achieve and maintain long-term renal response.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

Keywords

  • lupus nephritis
  • calcineurin inhibitors
  • voclosporin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have completed 52 weeks of treatment with study drug in the AURORA 1 study. Subjects who had a temporary interruption and successfully restarted study drug during the AURORA 1 study will be allowed with Medical Monitor approval.
  2. Written before any study-specific procedures were performed.
  3. In the opinion of the investigator, subject required continued therapy.
  4. Women of must continue to use effective and have a negative urine pregnancy test at Month 12.
  5. Subject is willing to continue taking oral mycophenolate mofetil (MMF) for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Currently taking or known need for any of the medications or food items listed in Section 7.8, Prohibited Therapy and Concomitant Treatment during the study.
  2. Subjects currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  3. A planned kidney transplant within study treatment period.
  4. Subjects with any medical condition which, in the Investigator's judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes.
  5. Subjects who are pregnant, breast feeding or, if of , not using adequate precautions.
  6. Vaccines using live organisms, virus or bacterial, while taking the study treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Voclosporin

    Voclosporin

    Drug: Voclosporin

  • Placebo comparator
    Placebo Oral Capsule

    Placebo

    Drug: Placebo Oral Capsule

Interventions

  • Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)

    Also known as: ISA247

  • DrugPlacebo Oral Capsule

    Voclosporin placebo, oral, 3 capsules twice daily (BID)

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.

    Number (and percent) of adverse events experienced during the AURORA 2 treatment period. To assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with LN.

    Time frame: Month 12 (AURORA 2 baseline) to Month 36

Secondary outcomes

  1. Number (and Percent) of Subjects in Renal Response

    Proportion of subjects in renal response defined as: * urine protein creatinine ratio (UPCR) of ≤0.5 mg/mg * estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 or no confirmed decrease from baseline in eGFR of \>20% * Received no rescue medication for LN * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during the 8 weeks prior to the renal response assessment.

    Time frame: Months 12 (AURORA 2 Baseline), 18, 24, 30 and 36

  2. Number (and Percent) of Subjects in Partial Renal Response

    Partial renal response defined as a 50% reduction from baseline in urine protein creatinine ratio (UPCR).

    Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36

  3. Renal Flare as Adjudicated by the Clinical Endpoints Committee (CEC).

    A patient could experience a flare from the point they achieved a response (or recovery). Renal flares were judged according to the following criteria: * A reproducible increase to UPCR \>1 mg/mg from a post-response baseline of \<0.2 mg/mg or * an increase to UPCR \>2 mg/mg from a post-response baseline between 0.2 to 1.0 mg/mg or * a doubling of UPCR for baseline values of UPCR \>1 mg/mg

    Time frame: Month 12 (AURORA 2 baseline) to Month 36

  4. Change From AURORA 1 Baseline (i.e., Month 0) in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

    Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Assessment of Systemic Lupus Erythematosus (SLE) Disease Activity within the last 10 days. It scores 24 disease descriptors across 9 organ systems which are summed to a minimum of \<2 (considered indicative of no activity) and maximum of 105 points. Scores are weighted and a score of 6 is considered clinically significant. Higher scores indicate worse disease activity.

    Time frame: Months 18, 24 and 36

  5. Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein to Creatinine Ratio (UPCR)

    Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in UPCR are indicative of better renal outcomes.

    Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36

  6. Change From AURORA 1 Baseline (i.e., Month 0) in Estimated Glomerular Filtration Rate (eGFR)

    Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. This endpoint incorporated Corrected eGFR values with a ceiling set to 90 mL/min/1.73 m\^2 Increases in eGFR levels are indicative of better renal outcomes.

    Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36

  7. Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein

    Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in Urine Protein levels are indicative of better renal outcomes.

    Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36

  8. Change From AURORA 1 Baseline (i.e., Month 0) in Serum Creatinine (SCr)

    Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Decreases in SCr levels can be indicative of better renal outcomes.

    Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36

07

Results

Posted Dec 14, 2022

Participant flow

Participant flow — Overall Study
MilestoneVoclosporinPlacebo Oral Capsule
Started116100
Completed10185
Not completed1515
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up31
Withdrew: Pregnancy31
Withdrew: Lack of efficacy20
Withdrew: Physician decision22
Withdrew: Protocol violation11
Withdrew: Adverse event02
Withdrew: Death03

Outcome measures

PrimaryAdverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.

Number (and percent) of adverse events experienced during the AURORA 2 treatment period. To assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with LN.

Time frame:
Month 12 (AURORA 2 baseline) to Month 36
Reported as:
Count of participants · Participants
Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.
ParticipantsVoclosporinPlacebo Oral Capsule
Any treatment-emergent adverse event (TEAE)10080
Treatment-related TEAE2821
Serious TEAE2123
TEAE leading to study drug discontinuation1117
TEAE leading to death03
Treatment-related TEAE leading to death00
Disease-related TEAE5034
Disease-related serious TEAE711
SecondaryNumber (and Percent) of Subjects in Renal Response

Proportion of subjects in renal response defined as: * urine protein creatinine ratio (UPCR) of ≤0.5 mg/mg * estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 or no confirmed decrease from baseline in eGFR of \>20% * Received no rescue medication for LN * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during the 8 weeks prior to the renal response assessment.

Time frame:
Months 12 (AURORA 2 Baseline), 18, 24, 30 and 36
Reported as:
Count of participants · Participants
Number (and Percent) of Subjects in Renal Response
ParticipantsVoclosporinPlacebo Oral Capsule
Renal Response - Month 126134
Renal Response - Month 187446
Renal Response - Month 246543
Renal Response - Month 306942
Renal Response - Month 365939
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.004 · Odds ratio (or): 2.30 · 95% CI 1.30 to 4.05
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.006 · Odds ratio (or): 2.19 · 95% CI 1.25 to 3.83
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.035 · Odds ratio (or): 1.81 · 95% CI 1.04 to 3.16
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.005 · Odds ratio (or): 2.24 · 95% CI 1.28 to 3.92
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.051 · Odds ratio (or): 1.74 · 95% CI 1.00 to 3.03
SecondaryNumber (and Percent) of Subjects in Partial Renal Response

Partial renal response defined as a 50% reduction from baseline in urine protein creatinine ratio (UPCR).

Time frame:
Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Reported as:
Count of participants · Participants
Number (and Percent) of Subjects in Partial Renal Response
ParticipantsVoclosporinPlacebo Oral Capsule
Partial Renal Response - Month 1210470
Partial Renal Response - Month 189668
Partial Renal Response - Month 249058
Partial Renal Response - Month 308561
Partial Renal Response - Month 368669
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.99 · 95% CI 1.88 to 8.46
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.008 · Odds ratio (or): 2.50 · 95% CI 1.28 to 4.88
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.001 · Odds ratio (or): 2.68 · 95% CI 1.46 to 4.91
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.040 · Odds ratio (or): 1.86 · 95% CI 1.03 to 3.34
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.290 · Odds ratio (or): 1.39 · 95% CI 0.75 to 2.58
SecondaryRenal Flare as Adjudicated by the Clinical Endpoints Committee (CEC).

A patient could experience a flare from the point they achieved a response (or recovery). Renal flares were judged according to the following criteria: * A reproducible increase to UPCR \>1 mg/mg from a post-response baseline of \<0.2 mg/mg or * an increase to UPCR \>2 mg/mg from a post-response baseline between 0.2 to 1.0 mg/mg or * a doubling of UPCR for baseline values of UPCR \>1 mg/mg

Time frame:
Month 12 (AURORA 2 baseline) to Month 36
Reported as:
Count of participants · Participants
Renal Flare as Adjudicated by the Clinical Endpoints Committee (CEC).
ParticipantsVoclosporinPlacebo Oral Capsule
Subjects without adequate response or with flares3946
Subjects with adequate response and wothout flares7754
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.045 · Odds ratio (or): 0.56 · 95% CI 0.32 to 0.99
SecondaryChange From AURORA 1 Baseline (i.e., Month 0) in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Assessment of Systemic Lupus Erythematosus (SLE) Disease Activity within the last 10 days. It scores 24 disease descriptors across 9 organ systems which are summed to a minimum of \<2 (considered indicative of no activity) and maximum of 105 points. Scores are weighted and a score of 6 is considered clinically significant. Higher scores indicate worse disease activity.

Time frame:
Months 18, 24 and 36
Reported as:
Least squares mean · Scores on a scale
Change From AURORA 1 Baseline (i.e., Month 0) in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)
Scores on a scaleVoclosporinPlacebo Oral Capsule
Month 18-6.4 (-7.4 to -5.4)-5.6 (-6.6 to -4.5)
Month 24-6.8 (-7.7 to -5.9)-6.1 (-7.0 to -5.1)
Month 36-6.8 (-7.7 to -5.9)-6.1 (-7.1 to -5.2)
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.238 · Least squares mean difference: -0.8 · 95% CI -2.1 to 0.5
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.215 · Least squares mean difference: -0.7 · 95% CI -1.8 to 0.4
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.246 · Least squares mean difference: -0.7 · 95% CI -1.8 to 0.5
SecondaryChange From AURORA 1 Baseline (i.e., Month 0) in Urine Protein to Creatinine Ratio (UPCR)

Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in UPCR are indicative of better renal outcomes.

Time frame:
Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Reported as:
Least squares mean · mg/mg
Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein to Creatinine Ratio (UPCR)
mg/mgVoclosporinPlacebo Oral Capsule
Month 12 (AURORA 2 baseline)-3.17 ± 0.164-2.52 ± 0.175
Month 18-3.05 ± 0.216-2.42 ± 0.232
Month 24-3.18 ± 0.188-2.41 ± 0.202
Month 30-3.12 ± 0.219-2.21 ± 0.235
Month 36-3.00 ± 0.222-2.52 ± 0.236
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.001 · Least squares mean difference: -0.65 · 95% CI -1.05 to -0.26
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.029 · Least squares mean difference: -0.63 · 95% CI -1.20 to -0.07
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.002 · Least squares mean difference: -0.77 · 95% CI -1.24 to -0.29
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.002 · Least squares mean difference: -0.91 · 95% CI -1.49 to -0.33
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.106 · Least squares mean difference: -0.48 · 95% CI -1.06 to -0.10
SecondaryChange From AURORA 1 Baseline (i.e., Month 0) in Estimated Glomerular Filtration Rate (eGFR)

Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. This endpoint incorporated Corrected eGFR values with a ceiling set to 90 mL/min/1.73 m\^2 Increases in eGFR levels are indicative of better renal outcomes.

Time frame:
Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From AURORA 1 Baseline (i.e., Month 0) in Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73 m^2VoclosporinPlacebo Oral Capsule
Month 12 (AURORA 2 baseline)1.8 ± 1.084.4 ± 1.15
Month 18-0.2 ± 1.311.6 ± 1.40
Month 24-1.3 ± 1.480.9 ± 1.60
Month 300.2 ± 1.56-0.8 ± 1.67
Month 36-0.2 ± 1.69-2.0 ± 1.81
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.041 · Least squares mean difference: -2.7 · 95% CI -5.3 to -0.1
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.292 · Least squares mean difference: -1.8 · 95% CI -5.1 to 1.6
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.282 · Least squares mean difference: -2.2 · 95% CI -6.1 to 1.8
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.659 · Least squares mean difference: 0.9 · 95% CI -3.2 to 5.1
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.438 · Least squares mean difference: 1.8 · 95% CI -2.8 to 6.4
SecondaryChange From AURORA 1 Baseline (i.e., Month 0) in Urine Protein

Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in Urine Protein levels are indicative of better renal outcomes.

Time frame:
Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Reported as:
Least squares mean · mg/dL
Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein
mg/dLVoclosporinPlacebo Oral Capsule
Month 12 (AURORA 2 baseline)-302.4 ± 16.91-234.6 ± 18.05
Month 18-297.8 ± 23.41-210.1 ± 25.15
Month 24-295.8 ± 17.10-248.8 ± 18.51
Month 30-304.7 ± 19.23-231.6 ± 20.67
Month 36-280.7 ± 22.66-261.7 ± 24.01
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.002 · Least squares mean difference: -67.7 · 95% CI -110.4 to -25.1
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.007 · Least squares mean difference: -87.7 · 95% CI -151.2 to -24.2
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.035 · Least squares mean difference: -47.0 · 95% CI -90.8 to -3.3
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.005 · Least squares mean difference: -73.1 · 95% CI -123.5 to -22.6
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.537 · Least squares mean difference: -19.0 · 95% CI -79.7 to 41.7
SecondaryChange From AURORA 1 Baseline (i.e., Month 0) in Serum Creatinine (SCr)

Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Decreases in SCr levels can be indicative of better renal outcomes.

Time frame:
Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Reported as:
Least squares mean · mg/dL
Change From AURORA 1 Baseline (i.e., Month 0) in Serum Creatinine (SCr)
mg/dLVoclosporinPlacebo Oral Capsule
Month 12 (AURORA 2 baseline)0.051 ± 0.0207-0.034 ± 0.0221
Month 180.078 ± 0.03000.027 ± 0.0323
Month 240.117 ± 0.04290.060 ± 0.0466
Month 300.094 ± 0.04940.129 ± 0.0534
Month 360.119 ± 0.05970.197 ± 0.0644
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.084 · 95% CI 0.035 to 0.134
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.209 · Least squares mean difference: 0.051 · 95% CI -0.029 to 0.131
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.353 · Least squares mean difference: 0.057 · 95% CI -0.064 to 0.178
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.616 · Least squares mean difference: -0.036 · 95% CI -0.176 to 0.105
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.372 · Least squares mean difference: -0.077 · 95% CI -0.248 to 0.094

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are events occurring from Month 12 of treatment (AURORA 2 baseline) up to 30 days after study treatment end in AURORA 2 (Month 37).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voclosporin0/116 (0%)21/116 (18.1%)84/116 (72.4%)
Placebo Oral Capsule3/100 (3%)23/100 (23%)60/100 (60%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventVoclosporinPlacebo Oral Capsule
Corona virus infectionInfections and infestations2/1165/100
Lupus nephritisRenal and urinary disorders2/1163/100
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/1163/100
Pneumonia viralInfections and infestations0/1162/100
OsteonecrosisMusculoskeletal and connective tissue disorders0/1162/100
Urinary tract infectionInfections and infestations2/1160/100
Disseminated tuberculosisInfections and infestations0/1161/100
GastroenteritisInfections and infestations1/1161/100
PneumoniaInfections and infestations1/1161/100
Radius fractureInjury, poisoning and procedural complications0/1161/100
Most frequent other events
Showing 10 of 27
Most frequent other events
EventVoclosporinPlacebo Oral Capsule
Urinary tract infectionInfections and infestations14/1168/100
Glomerular filtration rate decreasedInvestigations11/1165/100
Upper respiratory tract infectionInfections and infestations10/1163/100
Viral upper respiratory tract infectionInfections and infestations10/1164/100
DiarrhoeaGastrointestinal disorders10/1165/100
HypertensionVascular disorders10/1166/100
Corona virus infectionInfections and infestations5/1168/100
Oedema peripheralGeneral disorders4/1168/100
Herpes zosterInfections and infestations4/1167/100
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders5/1167/100

Baseline characteristics

Intent-to-Treat is comprised of all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for subjects that continued in AURORA 2. Intent-to-Treat population was used for analysis of all Outcome Measures. Safety population comprised all randomized subjects who took at least one dose of study treatment, and was used for AE and SAE reporting.

Age, Continuous
Age, Continuous(years)VoclosporinPlacebo Oral CapsuleTotal
Mean32.3 ± 10.3135.4 ± 11.6433.7 ± 11.03
Sex: Female, Male
Sex: Female, Male(Participants)VoclosporinPlacebo Oral CapsuleTotal
Female10588193
Male111223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VoclosporinPlacebo Oral CapsuleTotal
Hispanic or Latino393372
Not Hispanic or Latino7767144
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VoclosporinPlacebo Oral CapsuleTotal
American Indian or Alaska Native000
Asian303060
Native Hawaiian or Other Pacific Islander000
Black or African American18725
White444084
More than one race000
Unknown or Not Reported242347
Region of Enrollment
Region of Enrollment(participants)VoclosporinPlacebo Oral CapsuleTotal
United States15924
Southeast Asia292756
Europe383775
South America342761
Lupus Nephritis (LN) history
Lupus Nephritis (LN) history(years)VoclosporinPlacebo Oral CapsuleTotal
Years since diagnosis of systemic lupus erythematosus (SLE)6.6 ± 6.667.3 ± 6.856.9 ± 6.75
Years since diagnosis of lupus nephritis (LN)4.8 ± 5.275.0 ± 5.234.9 ± 5.24
Years since first instance of significant proteinuria (>500 mg/day)5.0 ± 5.154.7 ± 4.494.8 ± 4.85
Baseline Urine Protein Creatinine Ratio (UPCR)
Baseline Urine Protein Creatinine Ratio (UPCR)(mg/mg)VoclosporinPlacebo Oral CapsuleTotal
Mean3.941 ± 2.57663.868 ± 2.47643.907 ± 2.5251
Baseline estimated glomerular filtration rate (eGFR)
Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73 m^2)VoclosporinPlacebo Oral CapsuleTotal
Mean94.1 ± 31.3692.0 ± 28.0493.2 ± 29.82
08

Study locations

1 site
  • AURORA Investigative Center
    Oklahoma City, Oklahoma 73104, United States
09

References and documents

Publications

  • Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. PubMed 22879439 ↗
  • Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460. PubMed 22087680 ↗
  • Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309. PubMed 24330024 ↗
  • Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8. PubMed 23996158 ↗
  • Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4. PubMed 23736966 ↗
  • Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22. PubMed 21943027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Oct 2021, 24 months.

Results were first posted in Dec 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2018
First posted
Jul 24, 2018
StartActual
Sep 29, 2019
Primary completionActual
Oct 7, 2021
CompletionActual
Oct 7, 2021
Results first posted
Dec 14, 2022
Last update
Dec 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03597464
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Sep 29, 2019
Primary completion
Oct 7, 2021
Completion
Oct 7, 2021
Results posted
Dec 14, 2022
Last update
Dec 14, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion